Table 1 Patient main characteristics.
Patient | n(%) |
|---|---|
Gender | |
Male | 46(41.44) |
Female | 65(58.56) |
Disease | |
ALL | 71(63.96) |
BL | 5(4.50) |
PCNSL | 25(22.53) |
DLBCL | 8(7.21) |
ENKTCL | 2(1.80) |
Complication | |
Endocrine system diseases | 51(45.95) |
Cardiovascular system diseases | 44(39.64) |
Nervous system disease | 28(25.23) |
Genotyping and dosage of MTX | |
MTHFR C677T | |
CC (1516-5320 mg) | 23(20.72) |
CT (1400-8000 mg) | 55(49.55) |
TT (1730-9300 mg) | 33(29.73) |
MTHFR A1298C | |
AA (1400-9300 mg) | 92(82.88) |
AC (1500-5850 mg) | 16(14.41) |
CC (2000-6000 mg) | 3(2.71) |
ABCB1 C3435T | |
CC (1500-6000 mg) | 41(36.94) |
CT (1500-8000 mg) | 53(47.75) |
TT (1400-9300 mg) | 17(15.31) |
Toxicity and occurrence time after MTX treatment | |
Hematopoietic toxicity (5.3 ± 12.7 days) | 79(71.17) |
Hepatic toxicity and Renal toxicity (3.8 ± 7.6 days) | 86(77.48) |
Gastrointestinal toxicity (3.1 ± 6.2 days) | 33(29.73) |
Mucositis (6.0 ± 8.5 days) | 22(19.82) |
Treatment course when the toxicity occurred | |
Hematopoietic toxicity (1.2 treatment courses) | |
Hepatic toxicity and Renal toxicity (1.3 treatment courses) | |
Gastrointestinal toxicity (1.5 treatment courses) | |
Mucositis (1.8 treatment courses) | |
